Uncategorized
FDA approves Imbruvica as first therapy for chronic graft-versus-host disease
The FDA approved ibrutinib for the treatment of adults with chronic graft-versus-host disease who failed prior systemic therapy.Ibrutinib (Imbruvica; Pharmacyclics, Janssen) — a Bruton’s tyrosine kinase inhibitor already indicated for treatment of certain patients with leukemia, lymphoma and Waldenstrom’s macroglobulinemia — is the first therapy specifically approved to treat chronic GVHD.